

UCSF

UC San Francisco Previously Published Works

Title

Relationship of Age to Impulsivity and Decision Making: A Baseline Secondary Analysis of a Behavioral Treatment Study in Stimulant Use Disorders

Permalink

<https://escholarship.org/uc/item/62z967pv>

Journal

Journal of Addictive Diseases, 32(2)

ISSN

1055-0887

Authors

Kalapatapu, Raj K
Lewis, Daniel F
Vinogradov, Sophia
[et al.](#)

Publication Date

2013-04-01

DOI

10.1080/10550887.2013.795471

Peer reviewed



Published in final edited form as:

J Addict Dis. 2013 ; 32(2): 206–216. doi:10.1080/10550887.2013.795471.

Relationship of Age to Impulsivity and Decision-Making: A Baseline Secondary Analysis of a Behavioral Treatment Study in Stimulant Use Disorders

Raj K. Kalapatapu, MD^{1,2}, Daniel F. Lewis, BA³, Sophia Vinogradov, MD^{1,2}, Steven L. Batki, MD^{1,2}, and Theresa Winhusen, PhD³

¹Department of Psychiatry, University of California, San Francisco, CA, USA

²San Francisco Veterans Affairs Medical Center, San Francisco, CA USA

³Cincinnati Addiction Research Center, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, OH, USA

Abstract

Since stimulant use disorders (SUDs) remain prevalent across the lifespan, cognition is an important area of clinical care and research focus among aging adults with SUDs. This secondary analysis of a National Institute on Drug Abuse Clinical Trials Network study suggests that decision-making, verbal learning/memory, executive function and set shifting are important cognitive domains to screen clinically and treat in aging adults with SUDs. Some suggestions are made on how clinical treatment providers can practically use these results. An important direction for future research is the development of cognitively remediating treatments for impaired cognitive domains in aging adults with SUDs.

Keywords

cocaine; methamphetamine; aging; addiction; neurocognitive

Introduction

Stimulant use disorders (SUDs) remain a prevalent public health problem across the lifespan^{1–3}. One important research area in the treatment of SUDs is cognition^{4–7}, since cognitive changes are associated with clinical outcomes such as abstinence and treatment completion^{8,9}. The cognitive domains typically involved in SUDs include attention, memory, executive function^{10–13}, impulsivity^{14,15} and decision-making^{16–18}. As SUDs affect individuals across the lifespan and as evidence shows that SUDs remain prevalent even as adults grow older^{1,19–22}, knowledge of age-specific cognitive differences in individuals with SUDs might help inform the development of age-specific cognitive treatments.

Impulsivity and decision-making are important cognitive domains affected by aging^{23–28}. Some literature shows that impulsivity and decision-making improve with increasing age,

Address correspondence to: Raj K. Kalapatapu, MD, San Francisco Veterans Affairs Medical Center, Building 8 (Mental Health), Ground Floor, Room 4C, 4150 Clement Street, San Francisco, CA 94121. kalapatapu.raj.k@gmail.com, Phone: 415-221-4810 ext. 3075, Fax: 415-750-2187.

Contributors: Dr. Kalapatapu completed the background literature search. Mr. Lewis completed the statistical analyses. Dr. Kalapatapu wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

such as in the context of borderline personality disorder^{29, 30}. Other literature shows poorer impulsivity and decision-making with increasing age^{24, 27}. Because of brain abnormalities in a middle-aged adult with a SUD that are not typically found in a healthy middle-aged adult^{31, 32}, changes in cognitive domains in a middle-aged adult with a SUD may be greater than the changes in cognitive domains expected in a healthy middle-aged adult. Thus, additional literature on the interaction between age and impulsivity and between age and decision-making might help develop age-specific treatments targeting these important domains in individuals with SUDs.

There is limited research exploring the relationship between age and the domains of attention, memory, and executive function^{20, 33} in SUDs. However, there is even more limited research on the relationship between age and impulsivity and between age and decision-making in SUDs. One study of pathological gamblers, a classic disorder of impulsivity, found 18.2% of the males and 14.8% of the females in the older sub-group to report ever using cocaine³⁴. In another study of participants who reported using methamphetamine at least twice in the past 2 months, participants in the high impulsivity group were younger than those in the low impulsivity group³⁵.

A recently published behavioral treatment study ($n = 183$) of individuals with SUDs, which included a baseline neurocognitive battery containing impulsivity and decision-making measures³⁶, can help add to the literature on the relationship between age and impulsivity and between age and decision-making in SUDs. Exploring this relationship can help theoretically understand how the aging process, in the context of concurrent SUDs, affects the underlying brain regions responsible for complex cognitive domains like impulsivity and decision-making (e.g., orbitofrontal cortex, anterior cingulate cortex)^{18, 37}. Exploring this relationship can also help clinically develop cognitively remediating treatments (pharmacological and/or non-pharmacological) specific to affected cognitive domains^{4, 6, 7} in aging adults with SUDs. Thus, the aim of this secondary analysis was to assess the association of age on baseline measures of impulsivity and decision-making, among other neurocognitive measures. We hypothesized that increasing age would be associated with greater impulsivity and poorer decision-making.

Methods

Study Setting and Measures

Full details of the parent study³⁸ and the ancillary study³⁶ used for this analysis are described elsewhere. Briefly, the National Institute on Drug Abuse Clinical Trials Network (NIDA CTN) ancillary study enrolled 183 adult participants from 6 substance abuse community treatment programs nationwide. Participants had a current diagnosis of stimulant abuse or dependence based on the DSM-IV Checklist³⁹, endorsed methamphetamine or cocaine as their primary drug of choice, were seeking outpatient substance use disorder treatment, used stimulants in the prior 60 days, and were medically and psychiatrically stable enough for participation based on medical history and the Addiction Severity Index-Lite interview⁴⁰. Participants were randomized to Stimulant Abuser Groups to Engage in 12-Step (STAGE-12)³⁸ or treatment as usual (TAU). All participants provided informed consent, and the study was approved by the Institutional Review Boards of the participating sites.

Demographic variables included age, sex, race, ethnicity, education, marital status, and employment status. Substance use variables included substance use disorder diagnosis, age of onset of illicit stimulant use, years of illicit stimulant use, years of non-stimulant use, and route of illicit stimulant use. The Patient Health Questionnaire [PHQ⁴¹] was used to assess for depression, panic, and non-panic anxiety disorders.

The baseline neurocognitive measures assessed: impulsivity and decision-making [Barratt Impulsiveness Scale version-11 (BIS-11), Frontal Systems Behavioral Scale (FrSBe), Comalli-Kaplan version of the Stroop Color Word Task (C-K Stroop), Iowa Gambling Task (IGT)], verbal learning/memory [Rey Auditory Verbal Learning Test (RAVLT)], executive function and set shifting [Wisconsin Card Sorting Task (WCST)].

The self-report BIS-11 is designed to assess the personality/behavioral construct of impulsiveness in three sub-domains: attention, motor, non-planning⁴². A total score and a score for each sub-domain were calculated; higher scores indicate greater impulsiveness. The self-report version of the FrSBe is a brief, valid, and reliable assessment of three areas of functioning associated with the pre-frontal cortex: apathy, disinhibition, and executive dysfunction⁴³. An overall T-score and a T-score for each area of functioning were calculated; higher scores indicate poorer functioning. The C-K Stroop is an experimenter-administered measure that assesses impulsivity and response inhibition^{44, 45}. Interference errors, Interference time (in seconds), and a Derived Interference score (Interference minus color naming) were calculated; higher scores indicate poorer performance.

The IGT is a computerized gambling exercise that simulates real-life decision making via selection of 100 cards from four decks in 5 trial blocks⁴⁶. A Net Total T-score reflects a summary score, and each Net 1–5 T-score reflects a block of 20 cards; higher scores indicate the participant is more often choosing advantageous decks. Selection of cards 1–40 may be categorized as decision-making under ambiguity, and selection of cards 41–100 may be categorized as decision-making under risk^{47, 48}.

The RAVLT is an experimenter-administered measure of verbal learning and memory⁴⁹. Scores for Learning (sum of Trials I to V of List A), Trial B (free recall of Interference list B), and Trial VI (free recall of List A after Interference List B) were calculated; higher scores indicate better performance. The WCST is a computerized test of executive function and set shifting⁵⁰. T-scores for perseverative, nonperseverative and total errors, as well as perseverative responses, were calculated; higher scores indicate better performance.

Statistical Analysis

Descriptive statistics were conducted on the demographic, clinical and neurocognitive data. The Spearman's rho, a non-parametric test, assessed correlation between age and each neurocognitive measure. We analyzed all overall and sub-domain scores from all neurocognitive measures, because age can potentially affect various cognitive domains^{51–53}. After controlling for sex, years of education, race (Caucasian or African-American), ethnicity (Hispanic or Non-Hispanic), years of illicit stimulant use, route of illicit stimulant use, and substance use disorder diagnosis as indicated by the Corrected Akaike Information Criteria (AIC-C)^{54, 55}, the Wald statistic assessed the contribution of age in each regression analysis. We controlled for sex, as hormonal factors may mediate sex differences in impulsivity⁵⁶. We also controlled for other demographic features (years of education, race, ethnicity), since such factors can influence performance on neurocognitive measures⁵⁷. Since this was an exploratory secondary analysis, *p*-values < 0.05 were considered significant. All analyses were conducted using SAS version 9.3 (Cary, NC).

Results

Table 1 presents baseline demographic and clinical data. Table 2 presents baseline neurocognitive data, and Table 3 presents the contribution of age to the neurocognitive data. The age range of the sample was 19–60, primarily being late 30's. Most participants were female, high school educated, unmarried, and unemployed. Most participants had a primary cocaine use disorder diagnosis and used smoking as their primary route of illicit stimulant

use. Most participants also had a secondary alcohol use disorder diagnosis and smoked cigarettes. The mean values for the neurocognitive data in Table 2 are consistent with previous research (see Discussion).

BIS-11

Age was not significantly associated with any of the BIS-11 scores.

FrSBe

Age positively correlated with and was significantly associated with the current Executive dysfunction T-score ($\rho = 0.30$, $p = 0.03$) and the current Total T-score ($\rho = 0.27$, $p = 0.02$). Age was not significantly associated with the other FrSBe scores.

C-K Stroop

Age was not significantly associated with any of the C-K Stroop scores.

IGT

Age negatively correlated with and was significantly associated with the Net 1 T-score ($\rho = -0.23$, $p = 0.01$), and positively correlated with and was significantly associated with the Net 4 T-score ($\rho = 0.15$, $p = 0.04$) and Net 5 T-score ($\rho = 0.16$, $p = 0.049$). Age was not significantly associated with the other IGT scores.

RAVLT

Age negatively correlated with and was significantly associated with Trial VI ($\rho = -0.35$, $p = 0.01$) and Learning ($\rho = -0.33$, $p = 0.01$). Age was not significantly associated with Trial B.

WCST

Age negatively correlated with and was significantly associated with Perseverative errors T-score ($\rho = -0.37$, $p = 0.003$), Nonperseverative errors T-score ($\rho = -0.44$, $p = 0.0002$), Total errors T-score ($\rho = -0.42$, $p = 0.001$), and Perseverative responses T-score ($\rho = -0.38$, $p = 0.003$).

Discussion

The present analysis evaluated the association of age with impulsivity, decision-making, and other neurocognitive measures in cocaine- and/or methamphetamine-dependent patients. The results revealed that age was significantly associated with some of the scores on the FrSBe (positive correlation with executive dysfunction and total), IGT (Net 1 negative correlation, Net 4 and Net 5 positive correlation), and RAVLT (negative correlation with Trial VI and Learning). Age negatively correlated with and was significantly associated with all of the WCST scores. Age was not significantly associated with any of the BIS-11 and C-K Stroop scores. Thus, our hypotheses were partially supported.

Impulsivity and decision-making are complex cognitive domains that are not unidimensional^{42, 58}. The neurocognitive battery used in this study measured these domains using four different measures (BIS-11, FrSBe, C-K Stroop, IGT), and the significant association with age to only some scores may be due to specific sub-domains or underlying neural pathways tapped by these measures. Also, in the presence of SUDs, the aging process may be differentially affecting brain regions, such as the orbitofrontal cortex and the anterior cingulate cortex, which might explain the significant association with age to only some scores; such brain regions are vulnerable to the aging process^{59, 60}. However, since no

neuroimaging was conducted in this study, it is hard to speculate too much about what underlying neural correlates explain the results. It is also important to note that the range of mean/S.D. values for each neurocognitive measure (Table 2) are similar to the range of mean/S.D. values found in previous research in those with SUDs and/or are worse than controls: BIS-11^{61, 62}, FrSBe^{36, 63}, C-K Stroop⁴⁴, IGT⁶⁴, RAVLT^{65, 66}, and WCST⁶⁷.

Studies comparing older and younger adults on the IGT have found conflicting results⁶⁸. Our finding of age not correlating with the overall score is consistent with literature in healthy aging adults⁶⁹. Our mixed findings on the Net 1 score versus the Net 4 and Net 5 scores may be reflecting the complex relationship between age and SUDs interacting with a change in learning and decision-making while completing the IGT^{70, 71}. However, other literature has found differences of aging affecting decisions under ambiguity but not decisions under risk⁷². A future four-group study (older adults with SUDs, younger adults with SUDs, healthy older adults, healthy younger adults) using the IGT can help tease out this complex relationship.

The finding of age positively correlating with executive dysfunction on the FrSBe may be related to a loss of white matter structural integrity in the prefrontal cortex, which is found in both aging⁷³ and SUDs^{74, 75}. We were surprised to find age not correlating with any of the BIS-11 scores, as age and SUDs can affect the three sub-domains captured by the BIS-11. But, this finding is consistent with previous research on the BIS-11⁴². We were also surprised to find age not correlating with any of the C-K Stroop scores, but the sample's age range may not have been large enough to see age-related differences on this measure. The domains tapped by the RAVLT and WCST are consistent with both aging literature^{51–53}, where verbal learning/memory and executive function are affected by aging.

This analysis has several strengths. First, we had a fairly large sample size for this analysis, as we benefited from data collected from 6 substance abuse community treatment programs nationwide. Second, the non-pure sample of participants allows these findings to be generalized to clinical samples, where participants don't necessarily use one substance alone. Third, we were able to analyze four different measures of impulsivity and decision-making. Fourth, we controlled for sex, years of education, race, and ethnicity as indicated by the AIC-C, especially after a recent review⁷⁶ warned about appropriate interpretations when examining neurocognitive data in SUDs. Finally, since age and years of substance use can be naturally positively associated and since years of illicit stimulant use can significantly affect cognition^{6, 7}, we controlled for years of illicit stimulant use as indicated by the AIC-C in each regression analysis. As we still found significant results even after controlling for chronicity of illicit stimulant use, this further supports our position that a unique aging effect may be explaining these results over and above what is cognitively expected from chronicity of illicit stimulant use alone.

This analysis also has several limitations. First, the primary study was not specifically designed to assess the aims of this *post-hoc* analysis. Second, the amount of illicit stimulant use was not quantified in grams or dollar-value, which may have interacted with age to affect cognition. Third, the age span may not have been enough to see further age-related cognitive differences, since there were no individuals above age 60 in the sample. Fourth, a comprehensive neurocognitive battery was not conducted, which might also include an assessment of premorbid intelligence, attention, processing speed, and attentional bias. These untested cognitive domains may have been impaired and unknowingly influenced the tested cognitive domains. Finally, since this sample does not consist of participants with pure SUDs, the comorbid substance abuse and depressive/anxiety disorders (Table 2) may have contributed to inconsistent findings across impulsivity and decision-making.

Clinical treatment providers might consider practically using these results in a few ways when clinically managing an aging adult with an SUD. First, a neurocognitive assessment might be considered as a standard at an initial visit and at periodic follow-up visits (e.g., every 1 or 2 years). Previous research shows that even recognizing and screening for cognitive impairment in addiction populations is poor overall^{77–81}. Next, providers may consider adding adjunctive treatments in a patient's treatment plan to directly remediate the impaired cognitive domains (e.g., decision-making, executive function). Examples of adjunctive cognitively remediating treatments that have shown efficacy in addiction and other populations include pharmacological interventions^{4–7} (e.g., cholinesterase inhibitors, nicotinic agonists) and non-pharmacological interventions^{82–87} (e.g., computerized software, physical exercise). Finally, by capitalizing on unimpaired cognitive domains, treatment providers may modify their treatment approach to compensate for impaired cognitive domains. For example, instead of totally relying on verbal modalities, a provider may also consider using a visual modality (e.g., pictures, white board, computer screen) to convey information and compensate for a patient's impairment in verbal learning/memory. Such compensatory cognitive techniques have shown efficacy in other medical^{88–90} and psychiatric^{91–94} populations.

Conclusions

This analysis suggests that decision-making, verbal learning/memory, executive function and set shifting are important cognitive domains to screen clinically and potentially treat in adults with SUDs who continue to abuse stimulants as they grow older. Future directions include potentially conducting pre/post neuroimaging of frontal cortical regions in aging adults with SUDs, correlating neuroimaging findings with neurocognitive measures in aging adults with SUDs, and developing cognitively remediating treatments (pharmacological and/or non-pharmacological) specific to affected cognitive domains (e.g., decision-making, verbal learning/memory, executive function, set shifting) in aging adults with SUDs.

Acknowledgments

The National Institute on Drug Abuse (NIDA) contributed to the development of study design and initial protocol. Analysis, interpretation, manuscript preparation, and decision to submit the manuscript for publication was the sole responsibility of the authors. The publications committee of the NIDA Clinical Trials Network approved the final manuscript. The study in this manuscript was funded by the NIDA grant U10DA013732 (PI: Winhusen). Dr. Kalapatapu was funded by an Advanced Fellowship Program in Psychiatric Research/Neurosciences through the Veterans Affairs' Office of Academic Affiliations.

Source of Funding:

The authors alone are responsible for the content and writing of the manuscript. The National Institute on Drug Abuse (NIDA) contributed to the development of study design and initial protocol. Analysis, interpretation, manuscript preparation, and decision to submit the manuscript for publication was the sole responsibility of the authors. The publications committee of the NIDA Clinical Trials Network approved the final manuscript. The study in this manuscript was funded by the NIDA grant U10DA013732 (PI: Winhusen). Dr. Kalapatapu was funded by an Advanced Fellowship Program in Psychiatric Research/Neurosciences through the Veterans Affairs' Office of Academic Affiliations. Dr. Vinogradov is a paid consultant in Brain Plasticity, Inc., a company with a commercial interest in cognitive training software. Dr. Vinogradov is also a consultant to Amgen, Genentech, and Hoffman-LaRoche. The authors are unaware of any other affiliations, funding, or financial holdings that might be perceived as affecting the objectivity of this manuscript.

References

1. Arndt S, Clayton R, Schultz SK. Trends in substance abuse treatment 1998–2008: increasing older adult first-time admissions for illicit drugs. *Am J Geriatr Psychiatry*. 2011; 19:704–711. [PubMed: 21785290]

2. NIDA. [Last accessed on 3/10/2013.] Cocaine: Abuse and Addiction. Research Report Series: National Institute on Drug Abuse. 2009. <http://www.drugabuse.gov/sites/default/files/rccocaine.pdf>
3. Wu LT, Blazer DG. Illicit and nonmedical drug use among older adults: a review. *J Aging Health*. 2011; 23:481–504. [PubMed: 21084724]
4. Vocci FJ. Cognitive remediation in the treatment of stimulant abuse disorders: a research agenda. *Exp Clin Psychopharmacol*. 2008; 16:484–497. [PubMed: 19086769]
5. Sofuoglu M. Cognitive enhancement as a pharmacotherapy target for stimulant addiction. *Addiction*. 2010; 105:38–48. [PubMed: 20078461]
6. Sofuoglu M, Devito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. *Neuropharmacology*. 2013; 64:452–463. [PubMed: 22735770]
7. Brady KT, Gray KM, Tolliver BK. Cognitive enhancers in the treatment of substance use disorders: clinical evidence. *Pharmacol Biochem Behav*. 2011; 99:285–294. [PubMed: 21557964]
8. Aharonovich E, Amrhein PC, Bisaga A, Nunes EV, Hasin DS. Cognition, commitment language, and behavioral change among cocaine-dependent patients. *Psychol Addict Behav*. 2008; 22:557–562. [PubMed: 19071981]
9. Aharonovich E, Hasin DS, Brooks AC, Liu X, Bisaga A, Nunes EV. Cognitive deficits predict low treatment retention in cocaine dependent patients. *Drug Alcohol Depend*. 2006; 81:313–322. [PubMed: 16171953]
10. Jovanovski D, Erb S, Zakzanis KK. Neurocognitive deficits in cocaine users: a quantitative review of the evidence. *J Clin Exp Neuropsychol*. 2005; 27:189–204. [PubMed: 15903150]
11. Simon SL, Dean AC, Cordova X, Monterosso JR, London ED. Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. *J Stud Alcohol Drugs*. 2010; 71:335–344. [PubMed: 20409426]
12. Lundqvist T. Imaging cognitive deficits in drug abuse. *Curr Top Behav Neurosci*. 2010; 3:247–275. [PubMed: 21161756]
13. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. *J Neuropsychiatry Clin Neurosci*. 2003; 15:317–325. [PubMed: 12928507]
14. Tziortzis D, Mahoney JJ 3rd, Kalechstein AD, Newton TF, De la Garza R 2nd. The relationship between impulsivity and craving in cocaine- and methamphetamine-dependent volunteers. *Pharmacol Biochem Behav*. 2011; 98:196–202. [PubMed: 21215769]
15. Moeller FG, Dougherty DM, Barratt ES, Schmitz JM, Swann AC, Grabowski J. The impact of impulsivity on cocaine use and retention in treatment. *J Subst Abuse Treat*. 2001; 21:193–198. [PubMed: 11777668]
16. Cunha PJ, Bechara A, de Andrade AG, Nicastrì S. Decision-making deficits linked to real-life social dysfunction in crack cocaine-dependent individuals. *Am J Addict*. 2011; 20:78–86. [PubMed: 21175924]
17. Fernandez-Serrano MJ, Perez-Garcia M, Schmidt Rio-Valle J, Verdejo-Garcia A. Neuropsychological consequences of alcohol and drug abuse on different components of executive functions. *J Psychopharmacol*. 2010; 24:1317–1332. [PubMed: 20007413]
18. Lucantonio F, Stalaker TA, Shaham Y, Niv Y, Schoenbaum G. The impact of orbitofrontal dysfunction on cocaine addiction. *Nat Neurosci*. 2012; 15:358–366. [PubMed: 22267164]
19. Weiss LM, Petry NM. Interaction effects of age and contingency management treatments in cocaine-dependent outpatients. *Exp Clin Psychopharmacol*. 2011; 19:173–181. [PubMed: 21463074]
20. Kalapatapu RK, Campbell A, Aharonovich E, Hu MC, Levin FR, Nunes EV. Demographic and Clinical Characteristics of Middle-Aged versus Younger Adults Enrolled in a Clinical Trial of a Web-Delivered Psychosocial Treatment for Substance Use Disorders. *Journal of Addiction Medicine*. 2013; 7:66–72. [PubMed: 23340711]
21. Oslin DW. Evidence-based treatment of geriatric substance abuse. *Psychiatr Clin North Am*. 2005; 28:897–911. ix. [PubMed: 16325734]
22. Ersche KD, Jones PS, Williams GB, Robbins TW, Bullmore ET. Cocaine dependence: a fast-track for brain ageing? *Mol Psychiatry*. 2013; 18:134–135. [PubMed: 22525488]

23. Lynch DJ. Future time perspective and impulsivity in old age. *J Genet Psychol.* 1971; 118:245–252.
24. Mani TM, Bedwell JS, Miller LS. Age-related decrements in performance on a brief continuous performance test. *Arch Clin Neuropsychol.* 2005; 20:575–586. [PubMed: 15939183]
25. Deakin J, Aitken M, Robbins T, Sahakian BJ. Risk taking during decision-making in normal volunteers changes with age. *J Int Neuropsychol Soc.* 2004; 10:590–598. [PubMed: 15327737]
26. Green L, Myerson J, Lichtman D, Rosen S, Fry A. Temporal discounting in choice between delayed rewards: the role of age and income. *Psychol Aging.* 1996; 11:79–84. [PubMed: 8726373]
27. Isella V, Mapelli C, Morielli N, Pelati O, Franceschi M, Appollonio IM. Age-related quantitative and qualitative changes in decision making ability. *Behav Neurol.* 2008; 19:59–63. [PubMed: 18413919]
28. Marschner A, Mell T, Wartenburger I, Villringer A, Reischies FM, Heekeren HR. Reward-based decision-making and aging. *Brain Res Bull.* 2005; 67:382–390. [PubMed: 16216684]
29. Snyder S, Pitts WM Jr, Gustin Q. Absence of borderline personality disorder in later years. *Am J Psychiatry.* 1983; 140:271–272. [PubMed: 6849465]
30. Stevenson J, Meares R, Comerford A. Diminished impulsivity in older patients with borderline personality disorder. *Am J Psychiatry.* 2003; 160:165–166. [PubMed: 12505816]
31. Bartzokis G, Beckson M, Lu PH, Edwards N, Bridge P, Mintz J. Brain maturation may be arrested in chronic cocaine addicts. *Biol Psychiatry.* 2002; 51:605–611. [PubMed: 11955460]
32. Bartzokis G, Goldstein IB, Hance DB, Beckson M, Shapiro D, Lu PH, Edwards N, Mintz J, Bridge P. The incidence of T2-weighted MR imaging signal abnormalities in the brain of cocaine-dependent patients is age-related and region-specific. *AJNR Am J Neuroradiol.* 1999; 20:1628–1635. [PubMed: 10543632]
33. Kalapatapu RK, Vadhan NP, Rubin E, Bedi G, Cheng WY, Sullivan MA, Foltin RW. A pilot study of neurocognitive function in older and younger cocaine abusers and controls. *Am J Addict.* 2011; 20:228–239. [PubMed: 21477051]
34. Petry NM. A comparison of young, middle-aged, and older adult treatment-seeking pathological gamblers. *Gerontologist.* 2002; 42:92–99. [PubMed: 11815703]
35. Semple SJ, Zians J, Grant I, Patterson TL. Impulsivity and methamphetamine use. *J Subst Abuse Treat.* 2005; 29:85–93. [PubMed: 16135337]
36. Winhusen TM, Somoza EC, Lewis DF, Kropp FB, Horigian VE, Adinoff B. Frontal systems deficits in stimulant-dependent patients: Evidence of pre-illness dysfunction and relationship to treatment response. *Drug Alcohol Depend.* 2013; 127:94–100. [PubMed: 22771145]
37. Crews FT, Boettiger CA. Impulsivity, frontal lobes and risk for addiction. *Pharmacol Biochem Behav.* 2009; 93:237–247. [PubMed: 19410598]
38. Donovan DM, Daley DC, Brigham GS, Hodgkins CC, Perl HI, Garrett SB, Doyle SR, Floyd AS, Knox PC, Botoero C, Kelly TM, Killeen TK, Hayes C, Kau'ibaumhofer N, Seamans C, Zammarelli L. Stimulant abuser groups to engage in 12-step: a multisite trial in the National Institute on Drug Abuse Clinical Trials Network. *J Subst Abuse Treat.* 2013; 44:103–114. [PubMed: 22657748]
39. Hudziak JJ, Helzer JE, Wetzell MW, Kessel KB, McGee B, Janca A, Przybeck T. The use of the DSM-III-R Checklist for initial diagnostic assessments. *Compr Psychiatry.* 1993; 34:375–383. [PubMed: 8131381]
40. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The Fifth Edition of the Addiction Severity Index. *J Subst Abuse Treat.* 1992; 9:199–213. [PubMed: 1334156]
41. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. *JAMA.* 1999; 282:1737–1744. [PubMed: 10568646]
42. Stanford MS, Mathias CW, Dougherty DM, Lake SL, Anderson NE, Patton JH. Fifty years of the Barratt Impulsiveness Scale: An update and review. *Personality and Individual Differences.* 2009; 47:385–395.
43. Grace, J.; Malloy, PF. *Frontal Systems Behavioral Scale (FrSBe): Professional Manual.* Lutz, FL: Psychological Assessment Resources; 2001.

44. Streeter CC, Terhune DB, Whitfield TH, Gruber S, Sarid-Segal O, Silveri MM, Tzilos G, Afshar M, Rouse ED, Tian H, Renshaw PF, Ciraulo DA, Yurgelun-Todd DA. Performance on the Stroop predicts treatment compliance in cocaine-dependent individuals. *Neuropsychopharmacology*. 2008; 33:827–836. [PubMed: 17568399]
45. Winhusen T, Lewis D, Adinoff B, Brigham G, Kropp F, Donovan DM, Seamans CL, Hodgkins CC, Dicenzo JC, Botero CL, Jones DR, Somoza E. Impulsivity is associated with treatment non-completion in cocaine- and methamphetamine-dependent patients but differs in nature as a function of stimulant-dependence diagnosis. *J Subst Abuse Treat*. 2013 [Epub ahead of print 1/12/2013].
46. Bechara A, Damasio AR, Damasio H, Anderson SW. Insensitivity to future consequences following damage to human prefrontal cortex. *Cognition*. 1994; 50:7–15. [PubMed: 8039375]
47. Toplak ME, Sorge GB, Benoit A, West RF, Stanovich KE. Decision-making and cognitive abilities: A review of associations between Iowa Gambling Task performance, executive functions, and intelligence. *Clin Psychol Rev*. 2010; 30:562–581. [PubMed: 20457481]
48. Brand M, Recknor EC, Grabenhorst F, Bechara A. Decisions under ambiguity and decisions under risk: correlations with executive functions and comparisons of two different gambling tasks with implicit and explicit rules. *J Clin Exp Neuropsychol*. 2007; 29:86–99. [PubMed: 17162725]
49. Schmidt, M. *Rey Auditory Verbal Learning Test: A Handbook*. Lutz, FL: Psychological Assessment Resources; 2012.
50. Heaton, RK.; Chelune, GJ.; Talley, JL.; Kay, GG.; Curtiss, G. *Wisconsin Card Sorting Test Manual, Revised and Expanded*. Orlando, FL: Psychological Assessment Resources; 1993.
51. Keys BA, White DA. Exploring the relationship between age, executive abilities, and psychomotor speed. *J Int Neuropsychol Soc*. 2000; 6:76–82. [PubMed: 10761370]
52. Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. *Neuron*. 2004; 44:195–208. [PubMed: 15450170]
53. Grady C. The cognitive neuroscience of ageing. *Nat Rev Neurosci*. 2012; 13:491–505. [PubMed: 22714020]
54. Hook EB, Regal RR. Validity of methods for model selection, weighting for model uncertainty, and small sample adjustment in capture-recapture estimation. *Am J Epidemiol*. 1997; 145:1138–1144. [PubMed: 9199544]
55. Kletting P, Glatting G. Model selection for time-activity curves: the corrected Akaike information criterion and the F-test. *Z Med Phys*. 2009; 19:200–206. [PubMed: 19761098]
56. Perry JL, Carroll ME. The role of impulsive behavior in drug abuse. *Psychopharmacology (Berl)*. 2008; 200:1–26. [PubMed: 18600315]
57. Lezak, MD.; Howieson, DB.; Bigler, ED.; Tranel, D. *Neuropsychological Assessment*. 5. New York, NY: Oxford University Press; 2012.
58. Arce E, Santisteban C. Impulsivity: a review. *Psicothema*. 2006; 18:213–220. [PubMed: 17296034]
59. Resnick SM, Lamar M, Driscoll I. Vulnerability of the orbitofrontal cortex to age-associated structural and functional brain changes. *Ann N Y Acad Sci*. 2007; 1121:562–575. [PubMed: 17846159]
60. Pardo JV, Lee JT, Sheikh SA, Surerus-Johnson C, Shah H, Munch KR, Carlis JV, Lewis SM, Kuskowski MA, Dysken MW. Where the brain grows old: decline in anterior cingulate and medial prefrontal function with normal aging. *Neuroimage*. 2007; 35:1231–1237. [PubMed: 17321756]
61. Lane SD, Moeller FG, Steinberg JL, Buzby M, Kosten TR. Performance of cocaine dependent individuals and controls on a response inhibition task with varying levels of difficulty. *Am J Drug Alcohol Abuse*. 2007; 33:717–726. [PubMed: 17891664]
62. Bond AJ, Verheyden SL, Wingrove J, Curran HV. Angry cognitive bias, trait aggression and impulsivity in substance users. *Psychopharmacology (Berl)*. 2004; 171:331–339. [PubMed: 13680074]
63. Verdejo-Garcia A, Bechara A, Recknor EC, Perez-Garcia M. Executive dysfunction in substance dependent individuals during drug use and abstinence: an examination of the behavioral, cognitive and emotional correlates of addiction. *J Int Neuropsychol Soc*. 2006; 12:405–415. [PubMed: 16903133]

64. Hammers DB, Suhr JA. Neuropsychological, impulsive personality, and cerebral oxygenation correlates of undergraduate polysubstance use. *J Clin Exp Neuropsychol.* 2010; 32:599–609. [PubMed: 19937505]
65. Hoffman WF, Moore M, Templin R, McFarland B, Hitzemann RJ, Mitchell SH. Neuropsychological function and delay discounting in methamphetamine-dependent individuals. *Psychopharmacology (Berl).* 2006; 188:162–170. [PubMed: 16915378]
66. Fox HC, Jackson ED, Sinha R. Elevated cortisol and learning and memory deficits in cocaine dependent individuals: relationship to relapse outcomes. *Psychoneuroendocrinology.* 2009; 34:1198–1207. [PubMed: 19375236]
67. Rosselli M, Ardila A, Lubomski M, Murray S, King K. Personality profile and neuropsychological test performance in chronic cocaine-abusers. *Int J Neurosci.* 2001; 110:55–72. [PubMed: 11697211]
68. Buelow MT, Suhr JA. Construct validity of the Iowa Gambling Task. *Neuropsychol Rev.* 2009; 19:102–114. [PubMed: 19194801]
69. Carvalho JC, Cardoso Cde O, Shneider-Bakos D, Kristensen CH, Fonseca RP. The effect of age on decision making according to the Iowa gambling task. *Span J Psychol.* 2012; 15:480–486. [PubMed: 22774421]
70. Verdejo-Garcia A, Benbrook A, Funderburk F, David P, Cadet JL, Bolla KI. The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. *Drug Alcohol Depend.* 2007; 90:2–11. [PubMed: 17367959]
71. Bechara A, Damasio H, Tranel D, Damasio AR. Deciding advantageously before knowing the advantageous strategy. *Science.* 1997; 275:1293–1295. [PubMed: 9036851]
72. Zamarian L, Sinz H, Bonatti E, Gamboz N, Delazer M. Normal aging affects decisions under ambiguity, but not decisions under risk. *Neuropsychology.* 2008; 22:645–657. [PubMed: 18763884]
73. Caserta MT, Bannon Y, Fernandez F, Giunta B, Schoenberg MR, Tan J. Normal brain aging clinical, immunological, neuropsychological, and neuroimaging features. *Int Rev Neurobiol.* 2009; 84:1–19. [PubMed: 19501710]
74. Kim YT, Song HJ, Seo JH, Lee JJ, Lee J, Kwon DH, Yoo DS, Lee HJ, Suh KJ, Chang Y. The differences in neural network activity between methamphetamine abusers and healthy subjects performing an emotion-matching task: functional MRI study. *NMR Biomed.* 2011; 24:1392–1400. [PubMed: 21472808]
75. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff DL, Schuckit MA. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. *Neuropsychopharmacology.* 2002; 26:53–63. [PubMed: 11751032]
76. Hart CL, Marvin CB, Silver R, Smith EE. Is cognitive functioning impaired in methamphetamine users? A critical review. *Neuropsychopharmacology.* 2012; 37:586–608. [PubMed: 22089317]
77. Fals-Stewart W. Ability to counselors to detect cognitive impairment among substance-abusing patients: an examination of diagnostic efficiency. *Exp Clin Psychopharmacol.* 1997; 5:39–50. [PubMed: 9234038]
78. Schrimsher GW, Parker JD, Burke RS. Relation between cognitive testing performance and pattern of substance use in males at treatment entry. *Clin Neuropsychol.* 2007; 21:498–510. [PubMed: 17455033]
79. Horner MD, Harvey RT, Denier CA. Self-report and objective measures of cognitive deficit in patients entering substance abuse treatment. *Psychiatry Res.* 1999; 86:155–161. [PubMed: 10397417]
80. Shelton MD, Parsons OA. Alcoholics' self-assessment of their neuropsychological functioning in everyday life. *J Clin Psychol.* 1987; 43:395–403. [PubMed: 3597794]
81. Copersino ML, Fals-Stewart W, Fitzmaurice G, Schretlen DJ, Sokoloff J, Weiss RD. Rapid cognitive screening of patients with substance use disorders. *Exp Clin Psychopharmacol.* 2009; 17:337–344. [PubMed: 19803633]
82. Vinogradov S, Fisher M, de Villers-Sidani E. Cognitive training for impaired neural systems in neuropsychiatric illness. *Neuropsychopharmacology.* 2012; 37:43–76. [PubMed: 22048465]

83. Bickel WK, Yi R, Landes RD, Hill PF, Baxter C. Remember the future: working memory training decreases delay discounting among stimulant addicts. *Biol Psychiatry*. 2011; 69:260–265. [PubMed: 20965498]
84. Fals-Stewart W, Lam WK. Computer-assisted cognitive rehabilitation for the treatment of patients with substance use disorders: a randomized clinical trial. *Exp Clin Psychopharmacol*. 2010; 18:87–98. [PubMed: 20158298]
85. Subramaniam K, Vinogradov S. Cognitive training for psychiatric disorders. *Neuropsychopharmacology*. 2013; 38:242–243. [PubMed: 23147484]
86. Hindin SB, Zelinski EM. Extended practice and aerobic exercise interventions benefit untrained cognitive outcomes in older adults: a meta-analysis. *J Am Geriatr Soc*. 2012; 60:136–141. [PubMed: 22150209]
87. Vance DE, Keltner NL, McGuinness T, Umlauf MG, Yuan YY. The future of cognitive remediation training in older adults. *J Neurosci Nurs*. 2010; 42:255–64. quiz 265–266. [PubMed: 20968221]
88. Shum D, Fleming J, Gill H, Gullo MJ, Strong J. A randomized controlled trial of prospective memory rehabilitation in adults with traumatic brain injury. *J Rehabil Med*. 2011; 43:216–223. [PubMed: 21305237]
89. Winkens I, Van Heugten CM, Wade DT, Habets EJ, Fasotti L. Efficacy of time pressure management in stroke patients with slowed information processing: a randomized controlled trial. *Arch Phys Med Rehabil*. 2009; 90:1672–1679. [PubMed: 19801055]
90. Engelberts NH, Klein M, Ader HJ, Heimans JJ, Trenite DG, van der Ploeg HM. The effectiveness of cognitive rehabilitation for attention deficits in focal seizures: a randomized controlled study. *Epilepsia*. 2002; 43:587–595. [PubMed: 12060017]
91. Twamley EW, Vella L, Burton CZ, Heaton RK, Jeste DV. Compensatory cognitive training for psychosis: effects in a randomized controlled trial. *J Clin Psychiatry*. 2012; 73:1212–1219. [PubMed: 22939029]
92. Solanto MV, Marks DJ, Wasserstein J, Mitchell K, Abikoff H, Alvir JM, Kofman MD. Efficacy of meta-cognitive therapy for adult ADHD. *Am J Psychiatry*. 2010; 167:958–968. [PubMed: 20231319]
93. Londos E, Boschian K, Linden A, Persson C, Minthon L, Lexell J. Effects of a goal-oriented rehabilitation program in mild cognitive impairment: a pilot study. *Am J Alzheimers Dis Other Demen*. 2008; 23:177–183. [PubMed: 18182471]
94. Velligan DI, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Prihoda TJ, Miller AL. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. *Am J Psychiatry*. 2000; 157:1317–1323. [PubMed: 10910797]

Table 1

Baseline demographic and clinical data.

Demographic & Clinical Data (n = 183)	Mean (S.D.) or %	
Age	38.6 (9.3), range 19 – 60, median 38.4	
Age group 19–30	n = 47	
Age group 31–40	n = 58	
Age group 41–50	n = 66	
Age group 51–60	n = 12	
Male	31.7%	
Race ^a	Caucasian	43.4%
	African-American	46.2%
	Other/Mixed	10.4%
Hispanic	5.5% ^b	
Years of Education	12.0 (1.6)	
Currently married	22.7% ^c	
Employed in last 30 days	23%	
Age of 1 st illicit stimulant use	20.8 (6.1)	
Years of illicit stimulant use	12.2 (7.6)	
Years of non-stimulant use	14.8 (10.5)	
Smoking as primary route of illicit stimulant use	72.4% ^c	
Stimulant use disorder diagnosis ^b	Methamphetamine	25.8%
	Cocaine	68.7%
	Both	5.5%
Secondary substance use disorder diagnosis	Alcohol	60.7%
	Marijuana	38.3%
	Opiate	18%
	Benzodiazepine	8.2%
Currently smoking cigarettes	79.2%	
PHQ ^d Depression	27.3% ^e	

Demographic & Clinical Data (<i>n</i> = 183)	Mean (S.D.) or %
PHQ Panic disorder	17.8% ^f
PHQ Non-panic anxiety disorder	17.2% ^f

^a *n* = 182 due to missing data

^b *n* = 182 due to missing data

^c *n* = 181 due to missing data

^d PHQ = Patient Health Questionnaire

^e *n* = 176 due to missing data

^f *n* = 180 due to missing data

Table 2

Baseline neurocognitive data.

	Neurocognitive measure (n = 183)	Mean (S.D.)
BIS-11	Attention impulsiveness total score	17.7 (3.5)
	Motor impulsiveness total score	25.2 (4.3)
	Non-planning impulsiveness total score	24.5 (4.6)
	Total score	67.4 (8.9)
FrSBe	Current – Apathy T-score	76.9 (12.9)
	Current – Disinhibition T-score	77.5 (17.5)
	Current – Executive dysfunction T-score	73.0 (13.7)
	Current – Total T-score	79.4 (15.7)
C-K Stroop	Interference errors	1.9 (3.8)
	Interference time	118.5 (27.4)
	Derived interference score	54.0 (22.4)
	Net Total T-score	45.0 (9.6)
IGT	Net 1 T-score	52.9 (11.5)
	Net 2 T-score	47.6 (9.7)
	Net 3 T-score	44.5 (11.4)
	Net 4 T-score	43.4 (11.6)
	Net 5 T-score	42.7 (12.5)
RAVLT	Learning	45.1 (9.6)
	Trial B	5.2 (1.6)
	Trial VI	8.7 (3.0)
WCST	Perseverative errors T-score	47.2 (13.7)
	Nonperseverative errors T-score	42.3 (12.1)
	Total errors T-score	43.5 (12.7)
	Perseverative responses T-score	48.2 (14.4)

Table 3

Baseline adjusted neurocognitive data^a – association with age.

Neurocognitive measure		Parameter estimate with 95% confidence interval	Type III Wald Chi-Square ^b	p-value	Spearman's rho ^c
BIS-11	Attention impulsiveness total score	0.04 (-0.03, 0.12)	1.14	0.28	-0.17
	Motor impulsiveness total score	-0.07 (-0.15, -0.006)	3.33	0.07	-0.24
	Non-planning impulsiveness total score	0.03 (-0.05, -0.12)	0.65	0.42	-0.01
	Total score	-0.07 (-0.24, 0.10)	0.63	0.43	-0.17
FrSBe	Current – Apathy T-score	0.22 (-0.04, 0.48)	2.75	0.10	0.20
	Current – Disinhibition T-score	0.27 (-0.10, 0.65)	2.10	0.15	0.03
	Current – Executive dysfunction T-score	0.28 (0.02, 0.54)	4.56	0.03	0.30
	Current – Total T-score	0.37 (0.05, 0.68)	5.28	0.02	0.27
C-K Stroop	Interference errors	0.05 (-0.01, 0.11)	2.36	0.12	0.21
	Interference time	0.41 (-0.21, 1.03)	1.71	0.19	0.25
	Derived interference score	0.19 (-0.33, 0.71)	0.52	0.47	0.20
	Net Total T-score	0.14 (-0.06, 0.34)	1.88	0.17	0.06
IGT	Net 1 T-score	-0.29 (-0.52, -0.07)	6.57	0.01	-0.23
	Net 2 T-score	0.09 (-0.10, 0.29)	0.88	0.35	0.03
	Net 3 T-score	0.12 (-0.12, 0.35)	0.99	0.32	0.06
	Net 4 T-score	0.24 (0.01, 0.48)	4.20	0.04	0.15
	Net 5 T-score	0.25 (-0.002, 0.49)	3.85	0.049	0.16
RAVLT	Learning	-0.22 (-0.39, -0.05)	6.66	0.01	-0.33
	Trial B	0.004 (-0.02, 0.03)	0.10	0.75	-0.13
	Trial VI	-0.08 (-0.14, -0.02)	6.40	0.01	-0.35
WCST	Perseverative errors T-score	-0.43 (-0.71, -0.15)	8.99	0.003	-0.37
	Nonperseverative errors T-score	-0.49 (-0.75, -0.23)	13.79	0.0002	-0.44
	Total errors T-score	-0.46 (-0.73, -0.18)	10.83	0.001	-0.42
	Perseverative responses T-score	-0.45 (-0.75, -0.15)	8.90	0.003	-0.38

^aControlling for sex, years of education, race (Caucasian or African-American), ethnicity (Hispanic or Non-Hispanic), years of illicit stimulant use, route of illicit stimulant use, and substance use disorder diagnosis as indicated by the Corrected Akaike Information Criteria.

^bDegrees of freedom for all results = 1

^cCorrelation between age and the respective neurocognitive measure. Calculated independent of regression.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript